IFITM1 and breast carcinoma: Next, we investigated the clinical significance of IFITM1 and PLSCR1 expression in AI-resistant (recurrence) breast cancer by performing IHC staining on normal breast tissue, primary breast tumors (N = 40) and AI-resistant recurrence breast tumors (N = 40).